Healthcare & Life Sciences
Kartos Therapeutics
United Stateskartosthera.com/
Kartos Therapeutics is a startup based in the United States, most recent round Series B, 1 tracked investor.
activeseries-b
series-b
Stage
1
Investors
About Kartos Therapeutics
Based in the United States, Kartos Therapeutics is a startup. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Kartos Therapeutics is a clinical-stage biopharmaceutical company developing navtemadlin (KRT-232), an oral MDM2 inhibitor, as a targeted therapy for selected solid tumors and hematological malignancies. The company focuses on translational development and clinical evaluation of this small-molecule oncology drug.
Explore Kartos Therapeutics's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.